NCT06735300View on ClinicalTrials.gov

Saliva PCR in Pregnant Women with COVID-19

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

October 7, 2022

Study Completion Date

October 7, 2022

Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
DRUG

Nirmatrelvir/Ritonavir (Paxlovid)

After providing the potential benefits and associated risks of antiviral treatment with Paxlovid, patients made well-informed decisions about whether or not to receive Paxlovid (300/100 mg nirmatrelvir/ritonavir, Pfizer Inc., New York, NY, USA) twice daily for 5 days.

Trial Locations (1)

704

National Cheng 68 Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER